Enhertu

Imported from official source

Enhertu Active substance Trastuzumab deruxtecan Holder     Daiichi Sankyo Belgium N.V.-S.A Status Running Indication treatment of adult patients with unresectable or metastatic HER2-positive (IHC 3+) solid tumours who have received prior treatment and who have no satisfactory treatment options Public documents Approbation   Information for the patient   Informed consent …

This version

Version
1 of 1
Recorded
November 09, 2026 08:32
Change
Initial
Content hash
a8d97ffe63bd7edac1ec24969ad17e36
All versions
Revision history

Officially records where a publication came from, not whether it is true. Imported records are reproduced from an organization's own official source.